|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1981-7-20
|
|
pubmed:abstractText |
The response of intramuscularly growing KHT sarcomas to the chemotherapeutic agent (1-(2-cloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) alone or simultaneously with the chemical radio-sensitizer misonidazole (MISO) was assessed using either a tumour growth-delay assay or an in vivo-in vitro tumour-excision assay. Median tumour growth delay following the combination of 20 mg/kg CCNU and either 0.5 or 1.0 mg/g MISO was 19.5 and 21.5 days, compared to 10 days for this CCNU dose alone. A similar degree of enhanced tumour response by MISO (factor of approximately 2 in tumour growth delay) was seen in RIF-1 tumours treated with 20 mg/kg CCNU plus 1.0 mg/g MISO. Clonogenic cell-survival studies with KHT sarcomas demonstrated that MISO at doses of 0.25, 0.5 or 1.0 mg/g given simultaneously with a range of CCNU doses produced dose-modifying factors (DMFs) of 1.9, 2.1 and 2.4 respectively. Normal tissue toxicity assessed by an LD50/7 assay led to DMFs of 1.2 and 1.4 for CCNU doses combined with 0.5 and 1.0 mg/g MISO. Thus in this animal tumour model the combination of CCNU and MISO appears to lead to a potential gain by a factor of approximately 1.7.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7225287-1120304,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7225287-1203897,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7225287-227821,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7225287-277228,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7225287-277242,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7225287-277250,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7225287-361145,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7225287-4097429,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7225287-4473266,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7225287-528267,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7225287-536261,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7225287-591407,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7225287-6053718,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7225287-6928244,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7225287-73379,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7225287-7349894,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7225287-7362769,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7225287-7394163,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7225287-7471058,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7225287-993091
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
43
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
367-77
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7225287-Animals,
pubmed-meshheading:7225287-Cell Survival,
pubmed-meshheading:7225287-Dose-Response Relationship, Drug,
pubmed-meshheading:7225287-Drug Therapy, Combination,
pubmed-meshheading:7225287-Female,
pubmed-meshheading:7225287-Lomustine,
pubmed-meshheading:7225287-Mice,
pubmed-meshheading:7225287-Misonidazole,
pubmed-meshheading:7225287-Nitroimidazoles,
pubmed-meshheading:7225287-Nitrosourea Compounds,
pubmed-meshheading:7225287-Sarcoma, Experimental,
pubmed-meshheading:7225287-Time Factors
|
|
pubmed:year |
1981
|
|
pubmed:articleTitle |
In vivo combination of misonidazole and the chemotherapeutic agent CCNU.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
